Genetic Analysis operates in medical technology. The company conducts research and development in the field of diagnostics, with the main focus on the human microbiome. The technology is based on the company's research platform and the products are used, for example, for testing and analysis of bacteria and other viruses. The largest operations are in the Nordic market.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Bio-Rad Luxembourg S.À.R.L. | 22,49 | 22,49 | 2024-12-31 |
| Avanza Bank AB | 10,32 | 10,32 | 2024-12-31 |
| Muen Invest AS | 6,65 | 6,65 | 2024-12-31 |
| Nordnet Bank AB | 4,98 | 4,98 | 2024-12-31 |
| Lucellum AS | 4,86 | 4,86 | 2024-12-31 |
| Ochrino AS | 4,16 | 4,16 | 2024-12-31 |
| S. Munkhaugen AS | 3,54 | 3,54 | 2024-12-31 |
| Molver AS | 2,93 | 2,93 | 2024-12-31 |
| Biohit Oyj | 2,88 | 2,88 | 2024-12-31 |
| Leif Jørgen Moger | 2,67 | 2,67 | 2024-12-31 |
2025-08-27 Delårsrapport 2025-Q2
2025-11-27 Delårsrapport 2025-Q3
2026-02-25 Bokslutskommuniké 2025
